Cambridge Laboratories Group Limited ("Cambridge"), the privately-owned specialty pharmaceutical company, announced that XENAZINE® (tetrabenazine), the first and only product approved for the treatment of chorea associated with Huntington's disease, has been launched in the US.


Following the US Food and Drug Administration's approval of XENAZINE® in August the product will be sold in the US by Ovation Pharmaceuticals, a leading biopharmaceutical company which develops and commercialises innovative medicines focused on diseases of the central nervous system (CNS), haematology and hospital-based products. Ovation will market XENAZINE® to US specialists through its 48-person sales force, who have considerable experience in CNS disorders.

The launch follows the acquisition of Cambridge's original marketing partner, Prestwick Pharmaceuticals, by Biovail in September this year. Under the agreement, Biovail will commercialise tetrabenazine in Canada (marketed under the Nitoman® brand name). Biovail will also supply XENAZINE® to Ovation for a variable percentage of the product's annual net sales, and will in turn pay a supply price of 50% of net sales to Cambridge.

Ovation will distribute XENAZINE® via a specialty pharmacy network, designed to both help streamline prescription fulfilment and provide specialized assistance to healthcare professionals, patients and caregivers, including addressing questions about the appropriate use of XENAZINE®.

Mr. Mark Evans, Chief Executive of Cambridge, commented: "The launch of XENAZINE® in the US is a significant milestone in Cambridge's history. We are delighted that XENAZINE® will be promoted in the US by Ovation, who we believe will be able to maximize XENAZINE®'s potential in this important market. This is the only treatment for what is a devastating disease and we are pleased that patients finally have a treatment to help alleviate their debilitating symptoms."